| Characteristic |
WBRT + SRS |
SRS Only |
p-value |
| Total, n=63 |
n=14 |
n=49 |
|
| Age, Mean (standard deviation) |
59.7 (13.3) |
57.9 (11.7) |
0.62a |
| Male |
10 (71.4%) |
34 (69.4) |
1.00c |
| Prior chemotherapy |
7 (50.0%) |
15 (30.6%) |
0.31b |
| Prior extracranial radiation |
0 (0.0%) |
6 (12.2%) |
0.39b |
| SRS treatments Median (range) |
1 (1-4) |
2 (1-9) |
0.01d* |
| Total Mets treated by SRS Median (range) |
3.5 (1-29) |
5 (1-41) |
0.68d |
| Mets treated at initial SRS Median (range) |
3 (1-11) |
1 (1-8) |
0.0501d |
| Tumor volume treated, cc Median (range) |
7.8 (1.2-32.4) |
6.9 (0.4-40.8) |
0.51d |
| Survival, mo Median (range) |
11.3 (2.9-107.0) |
24.0 (10.9-118.5) |
0.0007d* |
| Marginal SRS dose, Gy Median (range) |
16 (15-20) |
20 (14-22) |
0.0001d* |
| Proximity of baseline MRI to treatment, months Median (range) |
0.8 (-0.7-4.4) |
0.0 (-1.0-2.8) |
0.13d |
| Time to first graded imaging, months Median (range) |
11.2 (6.8-20.2) |
12.2 (9.6-14.9) |
0.20d |
| Time to second graded imaging, months Median (range) |
23.9 (21.4-29.2) |
24.4 (22.7-29.4) |
0.67d |
Caption: Mets indicates metastases; MRI: Magnetic Resonance imaging; SRS: Stereotactic Radiosurgery; WBRT:Whole-Brain Radiation Therapy.
*indicates significant value.
a. Based on student t-test
b. Based on Pearson chi-square test
c. Based on Fisher exact test
d. Based on Wilcoxon rank-sum test |
